

Lytic transglycosylase MltG cleaves in nascent peptidoglycan and produces short glycan strands

Jad Sassine^{a,1}, Manuel Pazos^a, Eefjan Breukink^b, Waldemar Vollmer^{a,*}

^a Centre for Bacterial Cell Biology, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

^b Membrane Biochemistry and Biophysics, Bijvoet Centre of Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Utrecht, Netherlands

ARTICLE INFO

Keywords:

Peptidoglycan
Lytic transglycosylase
Penicillin-binding protein

ABSTRACT

Bacteria encase their cytoplasmic membrane with peptidoglycan (PG) to maintain the shape of the cell and protect it from bursting. The enlargement of the PG layer is facilitated by the coordinated activities of PG synthesising and -cleaving enzymes. In *Escherichia coli*, the cytoplasmic membrane-bound lytic transglycosylase MltG associates with PG synthases and was suggested to terminate the polymerisation of PG glycan strands. Using pull-down and surface plasmon resonance, we detected interactions between MltG from *Bacillus subtilis* and two PG synthases; the class A PBP1 and the class B PBP2B. Using *in vitro* PG synthesis assays with radio-labelled or fluorophore-labelled *B. subtilis*-type and/or *E. coli*-type lipid II, we showed that both, *BsMltG* and *EcMltG*, are lytic transglycosylases and that their activity is higher during ongoing glycan strand polymerisation. MltG competed with the transpeptidase activity of class A PBPs, but had no effect on their glycosyltransferase activity, and produced glycan strands with a length of 7 disaccharide units from cleavage in the nascent strands. We hypothesize that MltG cleaves the nascent strands to produce short glycan strands that are used in the cell for a yet unknown process.

Introduction

Most bacteria are engulfed by peptidoglycan (PG), a mesh-like molecule that maintains the shape of the cell and protects it from bursting due to the turgor (Vollmer et al., 2008). Growing cells continuously synthesise, modify and cleave PG to maintain cell integrity (Vollmer et al., 2008). PG is synthesised from the precursor lipid II. Glycosyltransferases (GTases) polymerize glycan strands and DD-transpeptidases (TPases) form peptide crosslinks (Barrett et al., 2007; Egan et al., 2020; Lovering et al., 2012; Van Heijenoort, 2001). PG synthases comprise bifunctional class A penicillin-binding proteins (PBPs) with GTase and TPase activity, SEDS and MltG proteins with GTase activity, and monofunctional class B PBPs with TPase activity (Egan et al., 2015; Meeske et al., 2016; Taguchi et al., 2019).

In *Bacillus subtilis*, *BsPBP1* is the most abundant class A PBP with roles in PG synthesis during length growth and cell division (Claessen et al., 2008; Pedersen et al., 1999). *Escherichia coli* has two semi-redundant class A PBPs, *EcPBP1A* and *EcPBP1B*, with preferential roles in elongation and cell division, respectively (Banzhaf et al., 2012;

Bertsche et al., 2006; Yousif et al., 1985). *EcPBP1A* and *EcPBP1B* are activated by the outer membrane-anchored lipoproteins LpoA and LpoB, respectively (Paradis-Bleau et al., 2010; Typas et al., 2010). The SEDS proteins *BsFtsW* and *EcFtsW* interact with their cognate class B PBP, *BsPBP2B* and *EcPBP3*, respectively, and synthesise PG in the test tube (Frapont et al., 2011; Rohs et al., 2018; Sjødt et al., 2018; Taguchi et al., 2019).

In *B. subtilis* and *E. coli*, glycan strands terminate with 1,6-anhydro-MurNAc residues that harbours an intramolecular ring from C1 to C6 (Atrih et al., 1999; Glauner et al., 1988; Høltje et al., 1975). Anhydro-MurNAc sugars are synthesised by lytic transglycosylases (LTs) that catalyse the non-hydrolytic cleavage of the glycosidic bond between the N-acetylmuramic acid and N-acetylglucosamine (Høltje et al., 1975). *B. subtilis* has five known or predicted LTs, YomI, SleB, CwlQ, YuiC and SleC, of which some may play roles in the lysis of the spore cortex for germination (Kumazawa et al., 2007; Quay et al., 2015; Sudiarta et al., 2010; Smith et al., 2000). *E. coli* has nine LTs, of which MltA, MltB, MltC, MltD, MltE, MltF and RlpA are lipoproteins anchored to the outer membrane (Jorgenson et al., 2014; van Heijenoort, 2011), Slt is a

Abbreviations: PBP, penicillin-binding protein; PG, peptidoglycan; TPase, transpeptidase; GTase, glycosyltransferase; LT, lytic transglycosylase.

* Corresponding author.

E-mail address: Waldemar.vollmer@ncl.ac.uk (W. Vollmer).

¹ Current address: Department of Biochemistry, University of Oxford, Oxford, UK

<https://doi.org/10.1016/j.tcs.2021.100053>

Received 24 March 2021; Received in revised form 17 April 2021; Accepted 26 April 2021

Available online 1 May 2021

2468-2330/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

periplasmic enzyme (Höltje et al., 1975), and EcMltG an inner membrane protein (Yunck et al., 2016).

Bioinformatics analysis showed that EcMltG and its defining YceG domain are widely distributed in the bacterial domain (Yunck et al., 2016). EcMltG is not essential and cells lacking EcMltG have no growth defect but the overexpression of EcMltG in cells lacking the synthase EcPBP1B resulted in loss of rod shape and cell death (Yunck et al., 2016). Purified EcMltG has a weak activity against PG causing the release of glycan strands with anhydroMurNAc ends, and EcMltG associates with EcPBP1B and RodA but not with EcPBP1A, GTase inactive EcPBP1B E233Q or RodA D262A in bacterial two-hybrid experiments (Bohrhunter et al., 2020; Yunck et al., 2016), hence, EcMltG has been hypothesized to act as a terminase of glycan strand synthesis. In *Streptococcus pneumoniae*, SpMltG has an additional cytoplasmic domain of unknown function and the loss of SpMltG resulted in a growth defect and a more spherical cell shape (Tsui et al., 2016).

B. subtilis has two MltG homologues with a predicted YceG-like domain, the forespore germination-specific SleB (Moriyama et al., 1999), and YrrL. Here, we focused on YrrL which has 32% amino acid sequence identity and 50% similarity with EcMltG extending over 356 amino acid residues (Fig. S1). We renamed YrrL to BsMltG. We show that purified BsMltG interacts with several PBPs and that it has lytic transglycosylase activity on nascent glycan strands, but is inactive against crosslinked PG, producing short glycan strands with a length of 7 disaccharide residues.

Methods

Media and general methods

Bacterial strains and plasmids used in this work are listed in Tables S1 and S2, respectively, and primers are listed in Table S3. *E. coli* cells were cultivated in Luria Britani (LB). Fresh cultures were inoculated with overnight culture and grown at 30 or 37C with continuous shaking. For solid media, 1% agar (Bacteriological agar no. 1, Oxoid) was added in addition to the appropriate antibiotic concentration (50 µg/ml Kanamycin). Competent *E. coli* cells were produced according to Hanahan et al. (1991), and heat shock transformations were used for DH5α as described by Bergmans et al. (1981). DNA was purified using DNA purification kit (Quiagen) as per manufacturer's instructions.

Cloning of strains and plasmids

Plasmids were generated using a ligase-free cloning method, which requires 4 sets of primers and 2 DNA templates: plasmid DNA and genomic DNA. pET-28a(+) plasmid was amplified using JS128-JS129 primers, and inserts were amplified using the oligonucleotides in Table S3. Plasmid construction was performed as described in Richardson et al. (2016). For site directed mutagenesis, a PCR reaction was performed using NEB Q5 high fidelity polymerase, plasmid construct as a template, and the corresponding primers from Table S3. Plasmids were purified using Mini-prep kit (Quiagen) as per manufacturer's instruction.

Protein purification

BsMltG, BsMltG E242A, BsPBP2B, EcMltG and EcMltG E218Q. BL21 (DE3) cells with the corresponding plasmids were grown in LB medium at 37C to OD600 0.5. Gene expression was induced with 1 mM IPTG for 3 h at 30C. Cells were pelleted by centrifugation (6371 × g / 4C/ 15 min) and resuspended in 40 ml buffer I (25 mM Tris/HCl, 1 M NaCl, pH 7.5) supplemented with protease inhibitor cocktail (PIC), phenylmethylsulfonyl fluoride (PMSF) and DNase (≈ 1 mg). Cells were sonicated for 3 × 20 s at 5, 16, 22, 33, 44 and 60 W. Membrane proteins were pelleted by ultracentrifuge at 133,907 × g at 4C, for 1 h, and the soluble fraction was discarded. The pellet was resuspended in running buffer

(25 mM Tris/HCl, 1 M NaCl, 20 mM imidazole, 2% Triton X-100, pH 7.5). Solubilised proteins were mixed gently with equilibrated Ni-NTA beads for 24 h at 4C. The mixture was applied to a gravity column and bound proteins were eluted in elution buffer (25 mM Tris/HCl, 400 mM imidazole, 1 M NaCl, 0.2% Triton X-100, pH 7.5). Restriction grade thrombin was added to eluted proteins, and samples were dialysed against 2 × 2 l of dialysis buffer I (25 mM Tris/HCl, 500 mM NaCl, pH 6.5) and 2 × 2 l of dialysis buffer II (25 mM Tris/HCl, 100 mM NaCl, pH 6.5) for overnight at 4C. Ion exchange chromatography was performed using an Äkta Prime FPLC with a HiTrap SP HP column. Dialysed protein was injected onto the column equilibrated with buffer I (25 mM Tris/HCl, 100 mM NaCl, 0.2% Triton X-100, pH 6.5). Bound protein was eluted in a 50 ml gradient to buffer II (25 mM Tris/HCl, 1 M NaCl, 0.2% Triton X-100, pH 7.5).

PBP1 and PBP1 (S390A). The purification protocol was adopted from (Rismondo et al., 2016) and modified. BL21 (DE3) cells with corresponding plasmids were grown in 5 l of LB medium with 50 µg/ml kanamycin and 20 ml/l auto-induction medium (250 mg/l glycerol, 100 g/L α-lactose and 25 g/L glucose) for 18 h at 30C. Cells were harvested, and sonicated. Cell membranes were pelleted by ultracentrifuge at 133907 × g then resuspended in resuspension buffer (50 mM Hepes/NaOH, 500 mM NaCl, 3 mM MgCl₂, 2% Triton X-100, 15% glycerol, 10 mM β-mercaptoethanol, pH 7.5). Membrane extracts were ultracentrifuged at 100000 × g and the supernatant was supplied with 20 mM imidazole. The first purification step was performed using a 5 ml HisTrap HP column attached to an ÄKTA Prime plus FPLC. Proteins were injected using running buffer (50 mM Hepes/NaOH, 500 mM NaCl, 3 mM MgCl₂, 0.2% reduced Triton X-100, 15% glycerol, 20 mM imidazole, pH 7.5) and eluted with elution buffer (same as running buffer with 250 mM imidazole). Protein samples were mixed with restriction grade thrombin and dialysed overnight at 4C against 3 l dialysis buffer (25 mM Hepes/NaOH, 300 mM NaCl, 10% glycerol, 0.2% Triton X-100, pH 8.5). Next, ion exchange chromatography was performed using an Äkta Prime FPLC with a HiTrap SP HP column. Dialysed protein samples were injected into the column using buffer I (Same as the dialysis buffer with 0.2% Triton X-100) and eluted in a 200 ml gradient with buffer II (10 mM Hepes/NaOH, 1 M NaCl, 3 mM MgCl₂, 0.2% Triton X-100, 12% glycerol, pH 7.5). The third purification step consisted of a size exclusion chromatography using a Superdex 75 column. Proteins were eluted with SEC buffer (10 mM Hepes/NaOH, 300 mM NaCl, 3 mM MgCl₂, 0.2% Triton X-100, 12% glycerol, pH 7.5).

PBP1B, PBP1B S510A and LpoB were purified as described in (Born et al., 2006). PBP1A and LpoA were purified as described in (Born et al., 2006) and (Jean et al., 2014), respectively.

In vitro pulldown assay

This method was adapted from (Egan et al., 2015). Proteins (1 µM) were mixed in 200 µl binding buffer (10 mM Hepes/NaOH, 10 mM MgCl₂, 150 mM NaCl, 0.05% Triton X-100, pH 7.5). Samples were applied to 100 µl of washed and equilibrated Ni-NTA superflow beads (Qiagen, The Netherlands) and incubated overnight at 4C with gentle mixing. The beads were then washed with wash buffer (10 mM Hepes/NaOH, 10 mM MgCl₂, 500 mM NaCl, 50 mM imidazole, 0.05% Triton X-100, pH 7.5) and boiled in SDS-PAGE loading buffer. Beads were pelleted by centrifugation and samples analysed by SDS-PAGE. Gels were stained with Coomassie brilliant blue (Roth, Germany).

Surface Plasmon Resonance (SPR) assay

This method was adapted from (Vollmer et al., 1999). Binding assays were performed at 25C in running buffer (10 mM Tris/Maleate, 150 mM NaCl, 0.05% Triton X-100, pH 7.5). Proteins to be injected (analyte) were dialysed into 2 × 1 l of dialysis buffer (10 mM Tris/Maleate, 150 mM NaCl, pH 7.5) then centrifuged using a Beckman TLA120.2 rotor (90000 rpm, 30 min, 4C) to remove aggregates. The concentration of the

protein was measured and the analytes were diluted in running buffer to 6 concentration ranges from 0 to 500 nM. It was important to make sure the Triton X-100 level in the analyte was as close to the running buffer as possible. SigmaPlot software (windows version 13.0) was used for kinetic calculations. Several repeats (at least 3) were required across a range of analyte concentrations. The K_D (nM) of ligand binding was based on the assumption of a one site saturation with the use of the equation $y = B_{max} \times x / (K_D + x)$ where y is the response (RU) for an analyte concentration in (nM), and B_{max} is the maximum response recorded (RU).

In vitro glycosyltransferase activity assay

For assay using radio-labelled *B. subtilis* or *E. coli* lipid II, experiments were performed as published (Egan and Vollmer, 2016). For assay using ATTO-550 lipid II, experiments were performed as published in (Barrett et al., 2007; van't Veer et al., 2016) with modifications according to (Egan et al., 2018). Glycan strands were separated by Tris-Tricine SDS-PAGE.

In vitro peptidoglycan synthesis assay

This method was performed as in (Cleverley et al., 2016) for *BsPBP1*,

and as in (Bertsche et al., 2005) for *EcPBP1B* and *EcPBP1A*. For HPLC analysis, a linear gradient was used at 55C for 90 min, from 100% solvent A (50 mM sodium phosphate pH 4.31 + 0.0002% NaN₃) to 100% solvent B (75 mM sodium phosphate, 15% methanol, pH 4.75) for *BsPBP1* and *EcPBP1B* samples, and solvent B (75 mM sodium phosphate, 30% methanol, pH 4.75) for *EcPBP1A* samples.

Cell wall purification and muropeptide analysis

This method was adapted from (Atrih et al., 1999) and modified as per (Bisicchia et al., 2011).

Results

BsMltG interacts with *BsPBP1* and *BsPBP2B*

EcMltG presumably associates with *EcPBP1B* based on bacterial two-hybrid experiments (Yunck et al., 2016). To test if *BsMltG* interacts with a class A PBP, we purified hexahistidine tagged *BsMltG* (His-*BsMltG*) and tested its possible interaction with *BsPBP1* in a pull-down experiment. SDS-PAGE analysis shows that His-*BsMltG* bound to Ni-NTA, and *BsPBP1* was not retained by the beads in the absence of His-*BsMltG* (Fig. 1A). However, *BsPBP1* was present in the bound fraction when




Fig. 1. *BsMltG* interacts with *BsPBP1* and is active during ongoing glycan strand polymerisation. (A) Pull-down assays performed to test if *BsMltG* interacts *BsPBP1*. The Coomassie-stained SDS-PAGE analysis shows His-*BsMltG* and *BsPBP1* in the applied and bound fractions suggesting that His-*BsMltG* pulled down *BsPBP1*. A, Applied; B, bound fractions. (B) Level of crosslinked and anhydro-N-acetylmuramic acid containing muropeptides generated in reactions with *BsPBP1* or *BsMltG* versions, or combinations, in assays with the *B. subtilis*-type lipid II. The PG product was digested with cellosyl and the resulting muropeptides were reduced and separated by HPLC. Representative HPLC chromatograms are shown in Fig. S4. Values are the mean ± standard deviation of three independent experiments. *BsMltG* has lytic transglycosylase activity in the presence of *BsPBP1*. *BsMltG* reduces the TPase activity of *BsPBP1*. Blue columns: TPase products (TP); Grey columns: LT products (LT); MltG E242A, catalytically inactive version; Amp; Ampicillin. **, P < 0.01 (T-test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

applied together with His-*BsMltG* suggesting the two proteins interact. The interaction between *BsMltG* and *BsPBP1* was also tested by surface plasmon resonance (SPR), but due to the high level of unspecific binding of proteins to the chip surface, we were not able to confirm the interaction by SPR.

We also tested if His-*BsMltG* interacts with the monofunctional cell division-specific *BsPBP2B* in pull-down experiment. SDS-PAGE analysis shows that His-*BsMltG* bound to Ni-NTA and *BsPBP2B* was not pulled down by the beads in the absence of His-*BsMltG* (Fig. S2A). Interestingly, *BsPBP2B* in the presence of His-*BsMltG* appeared in both the pre-Ni-NTA sample (applied) and bound fractions indicating that His-*BsMltG* pulled down *BsPBP2B* and suggesting that *BsPBP2B* interacts with His-*BsMltG*.

Next, we used SPR to study the interaction between *BsMltG* and *BsPBP2B* and determine the dissociation constant. We first immobilized ampicillin (amp) on two traces of a sensor chip. On one trace, *PBP2B* was covalently bound to the immobilized ampicillin (via its TPase domain). The second trace received no *BsPBP2B* and served as control. We next incubated both surfaces with β -lactamase to digest ampicillin molecules not bound to *PBP2B*. Upon the injection of *BsMltG*, the surface with immobilized *PBP2B* showed a significant increase in response unit during association (from 0 to 300 s) compared to the control surface upon the injection of *BsMltG* (Fig. S2B). The response almost reached equilibrium towards the end of the association (from 200 to 300 s). Subsequently, running buffer was injected after 300 s causing the dissociation of the analyte. These results indicate an interaction between *BsMltG* and *BsPBP2B*. The binding curve was generated by plotting the response in (RU) during equilibrium against analyte concentration (Fig. S2C). The K_D of the *BsMltG* and *BsPBP2B* interaction was 128 ± 28 nM, calculated based on a one site interaction model, from three independent experiments using Sigma Plot software. These results suggest that *BsMltG* interacts with both class A and B PBPs during PG synthesis in *B. subtilis*.

LT activity of *BsMltG*

EcMltG showed weak LT activity against purified *EcPG*, and the loss of *EcMltG* in cells resulted in longer glycan strands (Yunck et al., 2016). At first, we tested *BsMltG* LT activity against *B. subtilis* PG, however, *BsMltG* did not release muropeptides, suggesting that *BsMltG* was not active against PG (Fig. S3). Next, assuming that *BsMltG* processes glycan strands, and supported by the observed interaction of *BsMltG* with *BsPBP1* and *BsPBP2B*, we hypothesised that *BsMltG* might be active during ongoing PG synthesis. Since SEDS proteins were shown to be active only in the presence of 20–30% DMSO, which is known to disrupt some protein–protein interactions (Egan et al., 2018), we characterised the activity of *MltG* in the presence of class A PBPs which are active in the absence of DMSO. Consequently, the activity of purified *BsMltG* and *BsPBP1* were tested *in vitro* against the *B. subtilis* type lipid II (with amidated *meso*-Dap at position 3). A catalytically-inactive *BsMltG* variant possessing an Ala residue instead of the putative catalytic Glu242 was used in control experiments. *BsPBP1* polymerised glycan strands and crosslinked peptide stems producing PG, which was digested by cellosyl and analysed by HPLC (Fig. S4). *BsPBP1* alone produced a PG with 32.9% of the peptides participating in crosslinks, whereas, *BsMltG* alone had no activity against lipid II (Fig. 1B, S4). *BsPBP1* in the presence of *BsMltG* produced a PG with significantly reduced level of peptides in crosslinks (12.3%), and we noticed an additional peak (9.6%) corresponding to GlcNAc-anhydroMurNAC-pentapeptide (PentaAnh), identified by LC-MS/MS with 991.4340 amu (neutral mass, theoretical: 991.4346), eluting at 64 min. The peak corresponding to PentaAnh was not present in samples with *BsPBP1* and *BsMltG* E242A (Fig. S4), confirming that the E242 glutamate residue is essential for *BsMltG* LT activity. These results suggest that *BsMltG* has LT activity and reduces the TPase activity of *BsPBP1*.

Previously, *EcMltG* was shown to release only uncrosslinked

anhydroMurNAC muropeptides from purified PG (Yunck et al., 2016) and it might therefore favour uncrosslinked glycan strands for activity. Consequently, we added ampicillin to samples to block the TPase activity of *BsPBP1* (Fig. 1B and S4). *BsMltG* produced significantly more (25.7%) LT product in the presence of ampicillin-inhibited *BsPBP1*, suggesting that *BsMltG* shows enhanced activity against uncrosslinked, nascent PG strands. Next, to test if *BsMltG* requires ongoing PG synthesis by *BsPBP1* for activity, glycan strands were first synthesised by *BsPBP1* in the presence of ampicillin followed by digest with *BsMltG* (*BsPBP1* + Amp then *BsMltG* sample, Fig. 1B, and S4). In this sample there was approximately 5 times fewer LT products present as in the sample in which *BsMltG* was present during glycan strand synthesis, suggesting that *BsMltG* is most active during ongoing glycan strand polymerisation.

To test if *BsMltG* relies on both, ongoing PG synthesis and its interaction with *BsPBP1*, for higher activity, its activity was tested against nascent PG strands polymerized from *B. subtilis* lipid II by *EcPBP1B* (instead of *BsPBP1*). *BsMltG* was less active in the sample with *EcPBP1B* compared to *BsPBP1*, producing 4.5% PentaAnh (Fig. S5). Additionally, *BsMltG* showed high activity against glycan strands produced by *BsPBP1* from *E. coli* type lipid II (with non-amidated *meso*-Dap), suggesting that the amidation of the *meso*-DAP has no effect on the activity of *BsMltG* (Fig. S5).

To test if *BsMltG* has an *endo*-LT activity, PG material synthesised by *PBP1* in the presence of ampicillin and *BsMltG* was split into two aliquots, one was digested with the muramidase cellosyl and the other not, followed by HPLC analysis. An *exo*-LT activity of *BsMltG* should generate PentaAnh, which elutes in 1 peak at 64 min. However, PentaAnh was not present in the sample with *BsMltG* that was not digested with cellosyl. The sample digested first with *BsMltG* and then with cellosyl contained PentaAnh (from the MurNACAnh termini of the glycan strands) and Penta (from within the glycan strands and the GlcNAc termini) at a ratio of 1/5.2 (Fig. S5), showing that *BsMltG* was an *endo*-specific lytic transglycosylase that released glycan strands with an average length of 5–6 disaccharide units from nascent PG strands synthesised by *PBP1*.

EcMltG reduces the TPase activity of *EcPBP1A* and *EcPBP1B*

BsMltG was more active in the presence of ongoing glycan strand synthesis by *BsPBP1*, and reduced the TPase activity of the latter. Since *EcMltG* showed weak LT activity against *E. coli* PG and interacts with *EcPBP1B*, we hypothesised that *EcMltG* is active during PG synthesis by *EcPBP1A* or *EcPBP1B*. To test this hypothesis, we performed PG synthesis experiments using *EcPBPs* and *E. coli*-type lipid II. *EcPBP1A* alone produced PG with 41.1% of the peptides present in crosslinks (Fig. 2 and S6), however, *EcPBP1A* produced no crosslinks in the presence of *EcMltG* and the sample contained 44.3% PentaAnh (Fig. 2 and S6), suggesting that *EcMltG* inhibits the TPase activity of *EcPBP1A*. *EcPBP1A* produced fewer crosslinks (31.6%) also in the presence of catalytically inactive *EcMltG* E218Q, as expected this sample did not contain PentaAnh, suggesting that inactive *EcMltG* is also able to reduce the TPase activity of *EcPBP1A*. Additionally, the sample prepared with *EcPBP1A* (+Amp) and then digested with *EcMltG* contained significantly lower LT activity (5.0%) (Fig. 2 and S6), suggesting that, similar to *BsMltG*, *EcMltG* is most active during ongoing PG synthesis.

EcPBP1B alone produced PG with 49.9% peptides in crosslinks but in the presence of *EcMltG* approximately $3.5 \times$ fewer peptides were present in crosslinks (14.1%), and 28.7% PentaAnh was produced by *EcMltG* (Fig. 2 and S7). The presence of *EcMltG* E218Q resulted also in a significant decrease in TPase products generated by *EcPBP1B* (34.0%). *EcMltG* produced 25.4% PentaAnh in the presence of ongoing PG synthesis by a TPase inactive *EcPBP1B* S510A, close to the levels observed in the presence of active *EcPBP1B* with *EcMltG* (Fig. 2 and S7). However, *EcMltG* produced only 5.7% PentaAnh when it was added after PG synthesis by *EcPBP1B* S510A, confirming that *EcMltG* is more active during ongoing glycan strand polymerisation by either *EcPBP1A* or *EcPBP1B*.




Fig. 2. *EcMltG* favours ongoing glycan strand polymerisation for LT activity. Levels of crosslinked muropeptides (TP: blue columns) and LT product (LT: grey columns) obtained after cellosyl-digestion of the PG synthesised by *EcPBP1A*, *EcPBP1B* and/or *EcMltG*, from *E. coli*-type lipid II. Values are the mean \pm variation of two independent experiments. *EcMltG* has a lytic transglycosylase activity in the presence of *EcPBP1A* or *EcPBP1B*. *EcMltG* reduces the TPase activity of *EcPBP1A* and *EcPBP1B*. *EcPBP1B* S510A and *BsMltG* E218Q, catalytically inactive versions (controls); Amp, Ampicillin. **, $P < 0.01$; *, $P < 0.05$ (T-test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

EcMltG has lower activity in the presence of activated *EcPBP1A* and *EcPBP1B*.

The outer membrane-anchored lipoprotein LpoA activates *EcPBP1A* by direct interaction and stimulates its TPase activity, whereas, LpoB interacts with *EcPBP1B* and stimulates its GTase and TPase activities (Egan et al., 2014; Lupoli et al., 2014; Typas et al., 2010). To test the effect of MltG on glycan strand synthesis by Lpo-activated PBPs, we assayed the GTase and TPase activity of *EcPBPs*, and the LT activity of *EcMltG*, in the presence of the PBP activators. As expected, the activation of *EcPBP1A* by LpoA resulted in increased levels of peptides present in crosslinks (59.2%) compared to *EcPBP1A* alone (41.1%) (Figs. 2 and 3). The addition of *EcMltG* resulted in a significant decrease in peptides present in crosslinks to 16.2% (Fig. 3 and S8A) which, however, was above the 0% peptides in crosslinks without LpoA (Fig. 2). These results suggest that the activation of *EcPBP1A* rescued some of the TPase activity of PBP1A despite the presence of *EcMltG*. On the other hand, *EcMltG* synthesised 26.7% PentaAnh in the presence of *EcPBP1A* and LpoA (Fig. 3 and S8A), which was significantly lower than in the presence of *EcPBP1A* without LpoA (44.3%) (Fig. 2). Blocking the TPase activity of *EcPBP1A* with ampicillin (*EcPBP1A*, Amp, LpoA, *EcMltG* sample) resulted in a significant increase in PentaAnh (43.4%). These results show that the increase in TPase activity is matched by a decrease in LT activity, and vice versa, and suggest that *EcPBP1A* and *EcMltG* compete with each other for the glycan strand substrates.

EcPBP1B produced PG with 58.8% peptides in crosslinks in the presence of LpoB (Fig. 3 and S8B), however, the addition of *EcMltG* resulted in a significant decrease in TPase products to 41.7% and the production of 14.7% PentaAnh. The sample of *EcPBP1B* with LpoB and *EcMltG* E218Q also showed lower levels of TPase products (49.3%) compared to *EcPBP1B* with LpoB (Fig. 3 and S8B), suggesting that catalytically active or inactive *EcMltG* compromises the TPase activity of LpoB-activated *EcPBP1B*. *EcMltG* produced 20.9% PentaAnh in the presence of *EcPBP1B* S510A and LpoB (Fig. 3) compared to 25.4% in the presence of *EcPBP1B* S510A alone (Fig. 2B), suggesting that increased glycan synthesis rate resulted in a small decrease in *EcMltG* LT activity. Taken together, these results suggest that *EcMltG* processes growing PG strands and this LT activity decreases the TPase activity of class A PBPs, presumably by competing for the same PG strands, despite the activation by the Lpo protein.

MltG has no effect on the GTase activity of class A PBPs

The effect of MltG on the GTase activity of PBPs was tested using fluorescent-labelled Dansyl-lipid II. The polymerisation of glycan strands from Dansyl-lipid II and the digestion of these by a muramidase results in a decrease in fluorescence over time. As predicted, *EcMltG* or *BsMltG* alone did not cause a decrease in fluorescence over time demonstrating that both enzymes have no GTase activity (Fig. S9A and B). *BsPBP1* alone, or *BsPBP1* with *BsMltG* showed similar decrease in




Fig. 3. *EcMltG* is active in the presence of activated *EcPBP1A* and *EcPBP1B*. Level of crosslinked muropeptides (TP: blue columns) and LT products (grey columns) obtained after cellosyl-digestion of PG synthesised by Lpo-activated *EcPBP1A* and *EcPBP1B* in the presence or absence of *EcMltG* versions, in assays with *E. coli*-type lipid II. Values are the mean \pm variation of two independent experiments. *EcMltG* reduces the TPase activity of both, activated *EcPBP1A* and *EcPBP1B*. *EcMltG* had lower LT activity in the presence of Lpo-activated *EcPBP1A* or *EcPBP1B*, compared to *EcPBP1A* or *EcPBP1B* alone. *EcPBP1B* S510A and *EcMltG* E218Q, catalytically inactive versions (controls); Amp, Ampicillin. **, $P < 0.01$; *, $P < 0.05$ (T-test). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

fluorescence showing that *BsMltG* does not affect the GTase activity of *BsPBP1* (Fig. S9A). Similarly, *EcPBP1A* showed a decrease in fluorescence alone or in the presence of *EcMltG* and/or LpoA, suggesting that neither *EcMltG* nor LpoA affects the GTase activity of *EcPBP1A* (Fig. S9B). Confirming previous data (Egan et al., 2014), the addition of LpoB resulted in a faster decrease in fluorescence by *EcPBP1B*, but *EcMltG* had no effect on *EcPBP1B* alone or *EcPBP1B*/LpoB (Fig. S9C). These data show that *EcMltG* has no effect on the GTase activity of *PBP1B*, or its activation by LpoB.

EcMltG and *BsMltG* process glycan strands after the seventh disaccharide repeat

EcMltG and *BsMltG* cleaved newly synthesised glycan strands, suggesting a role in glycan length determination. To test this hypothesis, the activity of PBPs and MltG was tested against radioactive or fluorescent (ATTO-550) lipid II in the presence of ampicillin, and the resulting glycan strands were analysed by SDS-PAGE. *BsPBP1* alone produced long glycan strands that migrated at the top of the gel (Fig. 4A). The presence of *BsMltG* and not *BsMltG* E242A caused the formation of shorter glycan strands, with a distinctive increase in strands with 7 disaccharide units. Adding *BsMltG* after the strands were synthesized, also generated glycan strands with 7 disaccharide units, however, longer glycan strands were also detected suggesting that *BsMltG* was less active, consistent with the previous experiments (Fig. 1B). Testing the activity of *BsMltG* and/or *BsPBP1* against radioactive lipid II without the fluorophore produced similar results with a significant increase in short strands, albeit the glycan strand separation in the gel was poorer in this case (Fig. 4B). *EcMltG* was also tested using the fluorescent lipid II in the presence of *EcPBP1A* and *EcPBP1B* (Fig. 4C and D). *EcPBP1A* or *EcPBP1B* alone produced long glycan strands, however, the presence of *EcMltG* decreased the glycan strand length and, again, there was a significant increase in strands with 7 disaccharide units (Fig. 4C–D). This suggests that MltG from both species produces glycan strands with 7 disaccharide units when it cleaves the nascent strands during GTase reactions. Next, we tested if a faster rate of glycan synthesis would affect PG cleavage by *EcMltG* by testing *EcPBP1B* with LpoB and *EcMltG* against lipid II (Fig. 4D). *EcPBP1B* and LpoB produced glycan strands with a broader length distribution (Egan et al., 2018). The addition of

EcMltG resulted in a similar processing of the glycan strands and a clear increase in the strands with 7 disaccharide repeats, suggesting that the length of strands generated by *EcMltG* is independent from the rate of glycan polymerisation (Fig. 4D).

Discussion

BsMltG showed 67% sequence similarity and 53% identity to Lmo1499, a membrane bound lytic transglycosylase from *Listeria monocytogenes* (*LmMltG*). *LmMltG* has a transmembrane region followed by a LysM domain, involved in PG binding (Buist et al., 2008), and a catalytic domain close to the C-terminus of the protein (PDB: 4IIW), and this domain organization is conserved in *BsMltG* (Fig. 5A and S1). The LysM domain of MltG could mediate the binding to newly synthesised glycan strand in close proximity to the cytoplasmic membrane (Fig. 5). Interestingly, MltG produced glycan strands with 7 disaccharide residues, in the presence or absence of ongoing PG synthesis, suggesting that MltG binds a nascent glycan strand protruding from the membrane and cleaves it after 7 disaccharide units. In the model of *BsMltG* the distance between the LT catalytic residue E242 and one of the distant and conserved LysM domain residues Q80 is ~ 44 Å (Fig. 5A and S1), which corresponds to the length of 4–5 disaccharide units, given the length of one disaccharide unit of ~ 10 Å (Fig. 5A) (Carlström, 1962, 1957). Presumably, the length of the glycan strand produced by MltG depends also on the distance of the LT active site to the terminal disaccharide unit. Future work will explore whether MltG can be used to produce a sufficient amount of glycan strands with a desired length for biochemical or structural studies.

Maintaining the integrity of the PG layer is crucial to protect the cell from bursting due to its turgor. In this manuscript, we showed that MltG cleaves in nascent PG strands produced by class A PBPs and competes with their TPase activity even in the presence of the Lpo activators. These results are consistent with published data showing that the loss of MltG function suppressed a lethal deficiency in class A PBP activity (Bohrhunter et al., 2020), presumably by alleviating the reduction of TPase activity exerted by MltG on PBPs, and the decrease in PG cleavage. Interestingly, the absence or overexpression of *EcMltG* has no effect on the fitness of wild type *E. coli* cells (Yunck et al., 2016).

What is the cellular function of MltG? It was previously hypothesized




Fig. 5. Model of glycan strand cleavage by MltG. (A) BsmMltG residues were modelled using the crystal structure of Lmo1499 (PDB: 4IIW) as template (Yang et al., 2020). Highly conserved residues in the LysM domain are in cyan (Fig. S1), and the catalytic E242 residue is in red. The distance from the LT catalytic residue E242 to one of the distant and conserved LysM domain residues, Q80, is ~ 44 Å. (B) MltG is recruited to PG synthesis sites, presumably by interacting with PBPs, and competes with their TPase activity, cleaving in the nascent glycan strands to produce strands with 7 disaccharide units. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Conclusion

Our results suggest that inner-membrane bound lytic transglycosylases like MltG can modulate PG synthesis not only through their catalytic activities but also by interacting with and regulating the activities of PG synthases, and ultimately determining the structure of the PG.

CRediT authorship contribution statement

Jad Sassine: Conceptualization, Validation, Formal analysis, Investigation, Writing - original draft, Writing - review & editing, Visualization. **Manuel Pazos:** Investigation, Writing - review & editing. **Eefjan Breukink:** Resources, Writing - review & editing. **Waldemar Vollmer:** Conceptualization, Methodology, Validation, Data curation, Writing - original draft, Writing - review & editing, Supervision, Project administration, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This work was supported by grants from the European Union, Marie Curie ITN AMBER, 317338 (WV) and the UK Medical Research Council (MR/N002679/1) (WV). We thank Dr Joe Gray, Newcastle University, for MS analysis of muropeptides.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tcs.2021.100053>.

References

- Atrih, A., Bacher, G., Williamson, M.P., Foster, S.J., 1999. Analysis of peptidoglycan Structure from vegetative cells of *Bacillus subtilis* 168 and role of PBP 5 in peptidoglycan maturation. *J. Bacteriol.* 181, 3956–3966. <https://jb.asm.org/content/181/13/3956.long>.
- Banzhaf, M., van den Berg van Saparoea, B., Terrak, M., Fraipont, C., Egan, A., Philippe, J., Zapun, A., Breukink, E., Nguyen-Distèche, M., den Blaauwen, T., Vollmer, W., 2012. Cooperativity of peptidoglycan synthases active in bacterial cell elongation. *Mol. Microbiol.* 85, 179–194. <https://doi.org/10.1111/j.1365-2958.2012.08103.x>.
- Barrett, D., Andrew Wang, T.S., Yuan, Y., Zhang, Y., Kahne, D., Walker, S., 2007. Analysis of glycan polymers produced by peptidoglycan glycosyltransferases. *J. Biol. Chem.* 282, 31964–31971. <https://doi.org/10.1074/jbc.M705440200>.
- Bergmans, H.E.N., Van Die, I.M., Hoekstra, W.P.M., 1981. Transformation in *Escherichia coli*: stages in the process. *J. Bacteriol.* 146, 564–570. <https://jb.asm.org/content/146/2/564>.
- Bertsche, U., Breukink, E., Kast, T., Vollmer, W., 2005. *In vitro* murein (Peptidoglycan) synthesis by dimers of the bifunctional transglycosylase-transpeptidase PBP1B from *Escherichia coli*. *J. Biol. Chem.* 280, 38096–38101. <https://doi.org/10.1074/jbc.M508646200>.
- Bertsche, U., Kast, T., Wolf, B., Fraipont, C., Aarsman, M.E.G., Kannenberg, K., Von Rechenberg, M., Nguyen-Distèche, M., Den Blaauwen, T., Höltje, J.-V., Vollmer, W., 2006. Interaction between two murein (peptidoglycan) synthases, PBP3 and PBP1B, in *Escherichia coli*. *Mol. Microbiol.* 61, 675–690. <https://doi.org/10.1111/j.1365-2958.2006.05280.x>.
- Bisicchia, P., Bui, N.K., Aldridge, C., Vollmer, W., Devine, K.M., 2011. Acquisition of VanB-type vancomycin resistance by *Bacillus subtilis*: the impact on gene expression, cell wall composition and morphology. *Mol. Microbiol.* 81, 157–178.
- Bohrhunter, J.L., Rohs, P.D.A., Torres, G., Yunck, R., Bernhardt, T.G., 2020. MltG activity antagonizes cell wall synthesis by both types of peptidoglycan polymerases in *Escherichia coli*. *Mol. Microbiol.* mmi.14660 <https://doi.org/10.1111/mmi.14660>.
- Born, P., Breukink, E., Vollmer, W., 2006. *In vitro* synthesis of cross-linked murein and its attachment to sacculi by PBP1A from *Escherichia coli*. *J. Biol. Chem.* 281, 26985–26993. <https://doi.org/10.1074/jbc.M604083200>.
- Buist, G., Steen, A., Kok, J., Kuipers, O.P., 2008. LysM, a widely distributed protein motif for binding to (peptido)glycans. *Mol. Microbiol.* 68, 838–847. <https://doi.org/10.1111/j.1365-2958.2008.06211.x>.
- Burman, L.G., Park, J.T., 1983. Changes in the composition of *Escherichia coli* murein as it ages during exponential growth. *J. Bacteriol.* 155, 447–453. <https://jb.asm.org/content/155/2/447>.
- Carlström, D., 1962. The polysaccharide chain of chitin. *Biochim. Biophys. Acta* 59, 361–364.
- Carlström, D., 1957. The crystal structure of α -chitin (poly-N-acetyl-D-glucosamine). *J. Biophys. Biochem. Cytol.* 3, 669–683. <https://doi.org/10.1083/jcb.3.5.669>.

- Catalano C.E., 2000. The terminase enzyme from bacteriophage lambda: a DNA-packaging machine. *Cell. Mol. Life. Sci.* 57, 128–148. <https://link.springer.com/article/10.1007/s000180050503>.
- Claessen, D., Emmins, R., Hamoen, L.W., Daniel, R.A., Errington, J., Edwards, D.H., 2008. Control of the cell elongation-division cycle by shuttling of PBP1 protein in *Bacillus subtilis*. *Mol. Microbiol.* 68, 1029–1046. <https://doi.org/10.1111/j.1365-2958.2008.06210.x>.
- Cleverley, R.M., Rismondo, J., Lockhart-Cairns, M.P., Van Bentum, P.T., Egan, A.J.F., Vollmer, W., Halbedel, S., Baldock, C., Breukink, E., Lewis, R.J., 2016. Subunit arrangement in GpsB, a regulator of cell wall biosynthesis. *Microb. Drug Resist.* 22, 446–460. <https://doi.org/10.1089/mdr.2016.0050>.
- Egan, A.J.F., Biboy, J., van't Veer, I., Breukink, E., Vollmer, W., 2015. Activities and regulation of peptidoglycan synthases. *Philos. Trans. R. Soc. B Biol. Sci.* 370, 20150031. <https://doi.org/10.1098/rstb.2015.0031>.
- Egan, A.J.F., Errington, J., Vollmer, W., 2020. Regulation of peptidoglycan synthesis and remodelling. *Nat. Rev. Microbiol.* 18, 446–460. <https://doi.org/10.1038/s41579-020-0366-3>.
- Egan, A.J.F., Jean, N.L., Koumoutsis, A., Bougault, C.M., Biboy, J., Sassine, J., Solovyova, A.S., Breukink, E., Typas, A., Vollmer, W., Simorre, J.P., 2014. Outer-membrane lipoprotein LpoB spans the periplasm to stimulate the peptidoglycan synthase PBP1B. *Proc. Natl. Acad. Sci. U. S. A.* 111, 8197–8202. <https://doi.org/10.1073/pnas.1400376111>.
- Egan, A.J.F., Maya-Martinez, R., Ayala, I., Bougault, C.M., Banzhaf, M., Breukink, E., Vollmer, W., Simorre, J.-P., 2018. Induced conformational changes activate the peptidoglycan synthase PBP1B. *Mol. Microbiol.* 110, 335–356. <https://doi.org/10.1111/mmi.14082>.
- Egan, A.J.F., Vollmer, W., 2016. Continuous fluorescence assay for peptidoglycan glycosyltransferases. *Methods Mol. Biol.* 1440, 171–184. https://doi.org/10.1007/978-1-4939-3676-2_13.
- Fraipont, C., Alexeeva, S., Wolf, B., van der Ploeg, R., Schloesser, M., den Blaauwen, T., Nguyen-Disteché, M., 2011. The integral membrane FtsW protein and peptidoglycan synthase PBP3 form a subcomplex in *Escherichia coli*. *Microbiology* 157, 251–259. <https://doi.org/10.1099/mic.0.040071-0>.
- Glauner, B., Höltje, J.V., 1990. Growth pattern of the murein sacculus of *Escherichia coli*. *J. Biol. Chem.* 265, 18988–18996. [https://doi.org/10.1016/S0021-9258\(17\)30613-0](https://doi.org/10.1016/S0021-9258(17)30613-0).
- Glauner, B., Höltje, J.V., Schwarz, U., 1988. The composition of the murein of *Escherichia coli*. *J. Biol. Chem.* 263, 10088–10095. <https://www.pnas.org/content/111/22/8197>.
- Hanahan, D., Jessee, J., Bloom, F.R., 1991. Plasmid transformation of *Escherichia coli* and other bacteria. *Meth. Enzymol.* 204, 63–113. [https://doi.org/10.1016/0076-6879\(91\)04006-A](https://doi.org/10.1016/0076-6879(91)04006-A).
- Höltje, J.V., Mirelman, D., Sharon, N., Schwarz, U., 1975. Novel type of murein transglycosylase in *Escherichia coli*. *J. Bacteriol.* 124, 1067–1076. <https://jbs.asm.org/content/124/3/1067>.
- Jean, N.L., Bougault, C.M., Lodge, A., Derouaux, A., Callens, G., Egan, A.J.F., Ayala, I., Lewis, R.J., Vollmer, W., Simorre, J.-P., 2014. Elongated structure of the outer-membrane activator of peptidoglycan synthesis LpoA: implications for PBP1A stimulation. *Structure* 22, 1047–1054. <https://doi.org/10.1016/j.str.2014.04.017>.
- Jorgenson, M.A., Chen, Y., Yahashiri, A., Popham, D.L., Weiss, D.S., 2014. The bacterial septal ring protein RlpA is a lytic transglycosylase that contributes to rod shape and daughter cell separation in *Pseudomonas aeruginosa*. *Mol. Microbiol.* 124, 1067–1076. <https://doi.org/10.1111/mmi.12643>.
- Kumazawa, T., Masayama, A., Fukuoka, S., Makino, S., Yoshimura, T., Moriyama, R., 2007. Mode of action of a germination-specific cortex-lytic enzyme, SleC, of *Clostridium perfringens* S40. *Biosci. Biotechnol. Biochem.* 71, 884–892. <https://doi.org/10.1271/bbb.60511>.
- Lovering, A.L., Safadi, S.S., Strynadka, N.C.J., 2012. Structural perspective of peptidoglycan biosynthesis and assembly. *Annu. Rev. Biochem.* 81, 451–478. <https://doi.org/10.1146/annurev-biochem-061809-112742>.
- Lupoli, T.J., Lebar, M.D., Markovski, M., Bernhardt, T., Kahne, D., Walker, S., 2014. Lipoprotein activators stimulate *Escherichia coli* penicillin-binding proteins by different mechanisms. *J. Am. Chem. Soc.* 136, 52–55. <https://doi.org/10.1021/ja410813j>.
- Meeske, A.J., Riley, E.P., Robins, W.P., Uehara, T., Mekalanos, J.J., Kahne, D., Walker, S., Kruse, A.C., Bernhardt, T.G., Rudner, D.Z., 2016. SEDS proteins are a widespread family of bacterial cell wall polymerases. *Nature* 537, 634–638. <https://doi.org/10.1038/nature19331>.
- More, N., Martorana, A.M., Biboy, J., Otten, C., Winkle, M., Serrano, C.K.G., Montón Silva, A., Atkinson, L., Yau, H., Breukink, E., den Blaauwen, T., Vollmer, W., Polissi, A., 2019. Peptidoglycan remodeling enables *Escherichia coli* to survive severe outer membrane assembly defect. *MBio* 10, e02729–e2818. <https://doi.org/10.1128/mBio.02729-18>.
- Moriyama, R., Fukuoka, H., Miyata, S., Kudoh, S., Hattori, A., Kozuka, S., Yasuda, Y., Tochikubo, K., Makino, S., 1999. Expression of a germination-specific amidase, sleB, of bacilli in the forespore compartment of sporulating cells and its localization on the exterior side of the cortex in dormant spores. *J. Bacteriol.* 181, 2373–2378. <https://doi.org/10.1128/jb.181.8.2373-2378.1999>.
- Paradis-Bleau, C., Markovski, M., Uehara, T., Lupoli, T.J., Walker, S., Kahne, D.E., Bernhardt, T.G., 2010. Lipoprotein cofactors located in the outer membrane activate bacterial cell wall polymerases. *Cell.* 143, 1110–1120. <https://doi.org/10.1016/j.cell.2010.11.037>.
- Pedersen, L.B., Angert, E.R., Setlow, P., 1999. Septal localization of penicillin-binding protein 1 in *Bacillus subtilis*. *J. Bacteriol.* 181, 3201–3211. <https://jbs.asm.org/content/181/10/3201>.
- Quay, D.H.X., Cole, A.R., Cryar, A., Thalassinou, K., Williams, M., Bhakta, S., Keep, N.H., 2015. Structure of the stationary phase survival protein YuiC from *B. subtilis*. *BMC Struct. Biol.* 15, 1–14. <https://doi.org/10.1186/s12900-015-0039-z>.
- Richardson, T.T., Harran, O., Murray, H., 2016. The bacterial DnaA-trio replication origin element specifies single-stranded DNA initiator binding. *Nature* 534, 412–416.
- Rismondo, J., Cleverley, R.M., Lane, H.V., Großhennig, S., Steglich, A., Möller, L., Mannala, G.K., Hain, T., Lewis, R.J., Halbedel, S., 2016. Structure of the bacterial cell division determinant GpsB and its interaction with penicillin-binding proteins. *Mol. Microbiol.* 99, 978–998. <https://doi.org/10.1111/mmi.13279>.
- Rohs, P.D.A., Buss, J., Sim, S.I., Squyres, G.R., Srisuknimit, V., Smith, M., Cho, H., Sjødt, M., Kruse, A.C., Garner, E.C., Walker, S., Kahne, D.E., Bernhardt, T.G., 2018. A central role for PBP2 in the activation of peptidoglycan polymerization by the bacterial cell elongation machinery. *PLoS Genet.* 14, e1007726. <https://doi.org/10.1371/journal.pgen.1007726>.
- Sjødt, M., Brock, K., Dobihal, G., Rohs, P.D.A., Green, A.G., Hopf, T.A., Meeske, A.J., Srisuknimit, V., Kahne, D., Walker, S., Marks, D.S., Bernhardt, T.G., Rudner, D.Z., Kruse, A.C., 2018. Structure of the peptidoglycan polymerase RodA resolved by evolutionary coupling analysis. *Nature* 556, 118–121. <https://doi.org/10.1038/nature25985>.
- Smith, T.J., Blackman, S.A., Foster, S.J., 2000. Autolysins of *Bacillus subtilis*: Multiple enzymes with multiple functions. *Microbiology* 146, 249–262. <https://doi.org/10.1111/1.4026364>.
- Sudiarta, I.P., Fukushima, T., Sekiguchi, J., 2010. *Bacillus subtilis* CwlQ (previous YjbJ) is a bifunctional enzyme exhibiting muramidase and soluble-lytic transglycosylase activities. *Biochem. Biophys. Res. Commun.* 398, 606–612. <https://doi.org/10.1016/j.bbrc.2010.07.001>.
- Taguchi, A., Walker, S., 2021. Biochemical reconstitution defines new functions for membrane-bound glycosidases in assembly of the bacterial cell wall. *bioRxiv* 2021.03.06.434200; doi: <https://doi.org/10.1101/2021.03.06.434200>.
- Taguchi, A., Welsh, M.A., Marmont, L.S., Lee, W., Sjødt, M., Kruse, A.C., Kahne, D., Bernhardt, T.G., Walker, S., 2019. FtsW is a peptidoglycan polymerase that is functional only in complex with its cognate penicillin-binding protein. *Nat. Microbiol.* 4, 587–594. <https://doi.org/10.1038/s41564-018-0345-x>.
- Tsui, H.-C.T., Zheng, J.J., Magallon, A.N., Ryan, J.D., Yunck, R., Rued, B.E., Bernhardt, T.G., Winkler, M.E., 2016. Suppression of a deletion mutation in the gene encoding essential PBP2b reveals a new lytic transglycosylase involved in peripheral peptidoglycan synthesis in *Streptococcus pneumoniae* D39. *Mol. Microbiol.* 100, 1039–1065. <https://doi.org/10.1111/mmi.13366>.
- Typas, A., Banzhaf, M., Den Berg, Van, Van Saparoea, B., Verheul, J., Biboy, J., Nichols, R.J., Zietek, M., Beilharz, K., Kannenberg, K., Von Rechenberg, M., Breukink, E., Den Blaauwen, T., Gross, C.A., Vollmer, W., 2010. Regulation of peptidoglycan synthesis by outer-membrane proteins. *Cell* 143, 1097–1109. <https://doi.org/10.1016/j.cell.2010.11.038>.
- van't Veer, I.L., Leloup, N.O.L., Egan, A.J.F., Janssen, B.J.C., Martin, N.I., Vollmer, W., Breukink, E., 2016. Site-specific immobilization of the peptidoglycan synthase PBP1B on a surface plasmon resonance chip surface. *ChemBioChem* 17, 2250–2256. <https://doi.org/10.1002/cbic.201600461>.
- van Heijenoort, J., 2011. Peptidoglycan hydrolases of *Escherichia coli*. *Microbiol. Mol. Biol. Rev.* 75, 636–663. <https://doi.org/10.1128/MMBR.00022-11>.
- Van Heijenoort, J., 2001. Formation of the glycan chains in the synthesis of bacterial peptidoglycan. *Glycobiology* 11, 25–36. <https://academic.oup.com/glycob/article/11/3/25R/677256>.
- Vollmer, W., Blanot, D., de Pedro, M.A., 2008. Peptidoglycan structure and architecture. *FEMS Microbiol. Rev.* 32, 149–167. <https://doi.org/10.1111/j.1574-6976.2007.00094.x>.
- Vollmer, W., von Rechenberg, M., Höltje, J.V., 1999. Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of *Escherichia coli*. *J. Biol. Chem.* 274, 6726–6734. <https://doi.org/10.1074/jbc.274.10.6726>.
- Yang, J., Anishchenko, I., Park, H., Peng, Z., Ovchinnikov, S., Baker, D., 2020. Improved protein structure prediction using predicted interresidue orientations. *Proc. Natl. Acad. Sci.* 117, 1496–1503. <https://doi.org/10.1073/pnas.1914677117>.
- Yousif, S.Y., Broome-Smith, J.K., Spratt, B.G., Beveridge, T., Tropini, C., Salick, M., Crone, W.C., Gopinathan, A., Huang, K.C., Weibel, D.B., et al., 1985. Lysis of *Escherichia coli* by beta-lactam antibiotics: deletion analysis of the role of penicillin-binding proteins 1A and 1B. *J. Gen. Microbiol.* 131, 2839–2845. <https://doi.org/10.1016/j.cels.2016.05.006>.
- Yunck, R., Cho, H., Bernhardt, T.G., 2016. Identification of MltG as a potential terminase for peptidoglycan polymerization in bacteria. *Mol. Microbiol.* 99, 700–718. <https://doi.org/10.1111/mmi.13258>.